News
DXCM
129.40
-6.24%
-8.61
DEXCOM SHARES DOWN 4.2% AFTER Q1 RESULTS
Reuters · 8h ago
DexCom Price Target Raised to $145.00/Share From $144.00 by Canaccord Genuity
Dow Jones · 9h ago
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
TipRanks · 9h ago
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. Rose sharply in today's pre-market trading. The company reported upbeat results for its first quarter. Tevogen Bio Holdings Inc. Shares gained 64.7% after falling over 43% on Thursday. Skechers U.S.A., Inc. And Snap Inc. Also rose in pre- market trading.
Benzinga · 10h ago
Dexcom (DXCM) Gets a Buy from Piper Sandler
TipRanks · 10h ago
Dexcom (DXCM) Gets a Buy from Stifel Nicolaus
TipRanks · 10h ago
DEXCOM INC <DXCM.O>: RAYMOND JAMES RAISES TARGET PRICE TO $160 FROM $151
Reuters · 10h ago
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
NASDAQ · 10h ago
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
TipRanks · 11h ago
Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of Intel Corporation fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter sales results. Boyd Gaming Corporation and Hertz Global Holdings also recorded losses. The Nasdaq futures were higher this morning, with the Nasdaq gaining over 150 points.
Benzinga · 11h ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
TipRanks · 12h ago
Dexcom’s Strong Q1 Performance and Upbeat 2024 Outlook Justify Buy Rating
TipRanks · 12h ago
Stocks Rally on Blockbuster Earnings from Alphabet and Microsoft
US stock indexes this morning are moderately higher as earnings from Microsoft and Alphabet boost the overall market. Mar personal spending and the Mar core PCE deflator rose more than expected, hawkish factors for Fed policy. European stock markets are higher and T-notes prices are higher as inflation concerns ease.
Barchart · 13h ago
DEXCOM INC <DXCM.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $145 FROM $144
Reuters · 15h ago
DexCom (DXCM) Q1 2024 Earnings Call Transcript
Dexcom's (DXCM) first quarter 2024 earnings conference call will be held on April 25, 2024. Dexcom's chairman, president, and CEO, Kevin Sayer, will discuss the company's performance. The company will also discuss its plans for the future. The call will also include comments on the G7.
The Motley Fool · 16h ago
Dexcom down 7% after hours despite quarterly beats, 2024 outlook updates
Dexcom down 7% after hours despite quarterly beats, 2024 outlook updates. Q1 2024 results beat on both lines. The continuous glucose monitor maker's updated 2024 revenue outlook range is now $4.20B-$4.35B. The company did not provide EPS guidance.
Seeking Alpha · 22h ago
Dexcom's profit beats estimates on strong glucose monitor demand
Dexcom's profit beats estimates on strong glucose monitor demand. Company's total revenue rose 24% to $921 million in the first quarter. But company's annual sales forecast was largely below estimates. The company's shares slid 7% after the bell. Company and rival Abbott dominate the market for continuous glucose monitors.
Reuters · 23h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. Fresh2 Group stock rose 10.61% and ResMed stock rose 6.85% in the same session. The company's Q3 earnings came out today.
Benzinga · 1d ago
*DexCom Narrows 2024 View To Rev $4.2B-$4.35B >DXCM
Dow Jones · 1d ago
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.